Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Results available

Methylphenidate for Ptsd and Stroke Veterans

NCT04885257
Conditions
PTSD, Stroke
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Fatigue, Cancer
Interventions
Methylphenidate, Placebo (Sugar Pill)
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer
Interventions
Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT)
Other · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, OROS-methylphenidate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
4 Years to 5 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 12 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 1Phase 2 Interventional Results available

The Reinforcing Mechanisms of Smoking in Adult ADHD

NCT00573859
Conditions
ADHD
Interventions
ADHD medication, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Irvine, California
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

NCT03326245
Conditions
Normal Physiology
Interventions
Methylphenidate Pill, Oral Placebo, Intravenous Placebo, Intravenous methylphenidate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional Results available

The Discriminative Effects of Tramadol in Humans

NCT00499746
Conditions
Opioid Abuse, Opioid Addiction, Stimulant Abuse, Stimulant Addiction
Interventions
tramadol, placebo, Hydromorphone, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Months to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate to Improve Balance and Walking in MS

NCT01896700
Conditions
Multiple Sclerosis
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Seattle, Washington
Conditions
Healthy
Interventions
Methylphenidate, Triazolam, Project: EVO, Placebo
Drug · Other
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
40 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Epilepsy
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Conditions
Healthy
Interventions
modafinil, methylphenidate, lorazepam, placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Conditions
Alzheimer's Disease, Apathy, Dementia
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Active, not recruiting Early Phase 1 Interventional

Targeting Drug Memories With Methylphenidate

NCT05978167
Conditions
Substance Use Disorder, Cocaine Use Disorder
Interventions
Methylphenidate, Memory reconsolidation, Placebo
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
26 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Conditions
Chronic Pain
Interventions
Methylphenidate, carbidopa-levodopa, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Conditions
Depression
Interventions
Citalopram, Methylphenidate (MPH), Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California